If approved, Valrox could become the most expensive drug in the world.
News & Analysis: BioMarin Pharmaceutical
Fast-approaching catalysts could make these biotech stocks top performers this year.
The business reported a handful of positive developments.
BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
BioMarin's stock is poised for big gains in 2020. Here's why.
BMRN earnings call for the period ending September 30, 2019.
BioMarin Pharmaceutical and Vertex Pharmaceuticals should prove to be outstanding growth vehicles in 2020 and beyond.
Long-term investors need to learn to stomach the ride.
BMRN earnings call for the period ending June 30, 2019.
Here's why this team of biotech experts are giddy about these stocks right now.